All In Biotech

Drug Trial Radar · NCT00004817

Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures

Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

385

Actual

Start

Feb 1991

Primary completion

Not stated

Sponsor

Sponsor type
NIH
Collaborators
Harborview Injury Prevention and Research Center
First posted
Feb 25, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury.

Conditions

  • Post-Traumatic Seizure Disorder
  • Head Injuries

Interventions

  • phenytoinDrug

  • valproate sodiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.